CRA-026440

SKU: orb1709984

Description

CRA-026440 (PCI-34051) is a potent, pan-HDAC inhibitor targeting multiple isoforms, including HDAC1, 2, 3, 6, 8, and 10, with Ki values in the low nanomolar range. It exhibits anti-tumor and anti-angiogenic properties, making it a useful research tool for studying colon cancer in both cellular and animal models.

Research Area

Cell Biology, Epigenetics & Chromatin, Molecular Biology

Key Properties

• CAS Number: 847460-34-8
• MW: 420.46
• Purity: 96.42% (May vary between batches)
• Formula: C₂₃H₂₄N₄O₄
• SMILES: O=C(NO)C1=CC=C(C#CCNC(=O)C2=CC=3C=C(OCCN(C)C)C=CC3N2)C=C1
• Target: Apoptosis,HDAC
• Solubility: DMSO:90 mg/mL (214.05 mM)

Bioactivity

• Target IC50:
  HDAC2:14 nM (ki)|HDAC6:15 nM (ki)|HDAC1:4 nM (ki)|HDAC8:7 nM (ki)|HDAC10:20 nM (Ki)|HDAC3:11 nM (ki)
• In Vivo:
  Administered intravenously at a dose of 100 mg/kg daily for three consecutive days, CRA-026440 significantly reduces tumor growth in mice bearing HCT116 or U937 human tumor xenografts.
• In Vitro:
  CRA-026440 exhibits anti-proliferative effects on HUVEC endothelial cells with a GI50 value of 1.41 μM. In tumor cells, treatment with CRA-026440 (0.1-10 μM; 18 hours) leads to the accumulation of acetylated histones and acetylated microtubule proteins, thereby inhibiting tumor cell growth and inducing apoptosis. CRA-026440 (0.1-10 μM; 5 days) inhibits ex vivo angiogenesis in a dose-dependent manner.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CRA026440, CRA-026440, CRA 026440, PCI-34051, HDAC8, HDAC, HDAC2, HDAC3, HDAC6, HDAC1, HDAC10

Compound Identifiers

PubChem CID

11619470